



Immunic, Inc. to Participate in Scientific, Industry and Investor Conferences in July

NEW YORK, June 28, 2021 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced participation in the following scientific, industry and investor conferences in July:

- June 30-July 3: **The International Federation of Psoriasis Association’s 6th World Psoriasis & Psoriatic Arthritis Conference 2021**. Dr. Thomas M Polasek, Clinical Pharmacology Registrar, Royal Adelaide Hospital, Australia, will present the first clinical experience with IMU-935, an orally available, selective inverse agonist of ROR γ t. The poster presentation will be accessible on the "Events and Presentations" section of Immunic's website at: ir.imux.com/events-and-presentations.
 - Abstract Number: 36568
 - Title: *Safety, tolerability and pharmacokinetics of single oral doses of IMU-935 in healthy volunteers: First clinical experience with an orally available small molecule inhibitor of IL-17*
 - Session Title: Current and new therapeutic modalities
 - Session Number: 4
- July 2-3 and 8-10, 2021: **16th Congress of ECCO** (European Crohn’s and Colitis Organization). Members of Immunic’s management and clinical teams will attend the virtual conference.
- July 13-14: **Ladenburg Thalmann Healthcare Conference**. Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic, will present a company overview on Tuesday, July 13, at 10:00 am ET. A live audio webcast of the presentation will be available on the “Events and Presentations” section of Immunic’s website at: ir.imux.com/events-and-presentations. An archived replay will be available on the company’s website for a period of 90 days.

About Immunic, Inc.

Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. The company is developing three small molecule products: its lead development program, IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect, is currently being developed as a treatment option for multiple sclerosis, ulcerative colitis, Crohn’s disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor ROR γ t, is targeted for development in psoriasis and Guillain-Barré syndrome. IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction. For further information, please visit: www.imux.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All



statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to management's participation in scientific, industry and investor conferences. Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management's current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the COVID-19 pandemic, risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient resources to meet business objectives and operational requirements, the fact that the results of earlier studies and trials may not be predictive of future clinical trial results, the protection and market exclusivity provided by Immunic's intellectual property, risks related to the drug development and the regulatory approval process and the impact of competitive products and technological changes. A further list and descriptions of these risks, uncertainties and other factors can be found in the section captioned "Risk Factors," in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2020, filed with the SEC on February 26, 2021, and in the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov or ir.imux.com/sec-filings. Any forward-looking statement made in this release speaks only as of the date of this release. Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all the contents of this press release.

Contact Information

Immunic, Inc.

Jessica Breu
Head of Investor Relations and Communications
+49 89 2080 477 09
jessica.breu@imux.com

US IR Contact

Rx Communications Group
Paula Schwartz
+1 917 322 2216
immunic@rxir.com

US Media Contact

KOGS Communication
Edna Kaplan
+1 781 639 1910
kaplan@kogspr.com